SOX10 directly induces the transcription of IRF4, a negative regulator of IRF1; thus, its inhibition can enhance tumor responsiveness to anti-PD1 therapy, as observed in mice subcutaneously implanted with murine D4M melanoma cells [87]. This evidence concerns the gene SOX10 and neoplasm.